Diabetes, obesity & metabolism · 2025
Safety and efficacy of the therapy with CD4 + CD25highCD127-T regulatory cells: When paediatric patient becomes adult.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bandura Marta, Piotrowska-Mieczkowska Magdalena, Hennig Matylda, Gliwiński Mateusz, Wołoszyn-Durkiewicz Anna, Schoenhoff Julia, Dybowska Milena, Alska Anna, Gutknecht Piotr, Trzeciak Bartosz, Stefańska Katarzyna, Glasner Paulina, Hellmann Marcin, Burzyński Jacek, Michalak Arkadiusz, Siebert Janusz, Iwaszkiewicz-Grześ Dorota, Myśliwiec Małgorzata, Trzonkowski Piotr
Аннотация
AIM: CD4 + CD25highCD127-T regulatory cells (Tregs) remain a drug candidate for immunotherapy of type 1 diabetes. We completed three trials testing Tregs in recently diagnosed type 1 diabetes children. Here, we looked for long-term safety and efficacy aspects important in the authorisation of this therapy.
MATERIALS AND METHODS: We re-examined 51 participants exposed to Treg therapy between 7.5 and 12 years prior to assessment. Based on previous assignments, we assessed the following subgroups treated with Tregs and anti-CD20 antibody (Tregs+antiCD20, N = 9), with 1 or 2 doses of Tregs only (Tregs 1 dose, N = 10 and Tregs 2 doses, N = 8). The exposed participants were compared with those who received standard of care therapy (SoC control, N = 24) as part of previous studies. The patients underwent diabetes-oriented tests as well as non- to minimal invasive evaluation of the anatomy and function of the eye, micro- and microcirculation, endocrine system, genitourinary tract and fertility, kidney and liver profiles, detailed biochemistry lab tests and safety screening. Over 700 variables were analysed.
RESULTS: Tregs+antiCD20 group was superior to SoC control group in terms of C-peptide secretion in mixed-meal tolerance test, the time of insulin independence and remission. No clinically relevant between-groups differences were found in other performed examinations. Importantly, no severe adverse effects including tumors or deaths were reported.
CONCLUSIONS: We confirmed the long-term safety and efficacy of the therapy. Due to the superior efficacy profile, the combined treatment with Tregs and antiCD20 antibody should be considered as a routine therapy for recent-onset type 1 diabetes patients.
MATERIALS AND METHODS: We re-examined 51 participants exposed to Treg therapy between 7.5 and 12 years prior to assessment. Based on previous assignments, we assessed the following subgroups treated with Tregs and anti-CD20 antibody (Tregs+antiCD20, N = 9), with 1 or 2 doses of Tregs only (Tregs 1 dose, N = 10 and Tregs 2 doses, N = 8). The exposed participants were compared with those who received standard of care therapy (SoC control, N = 24) as part of previous studies. The patients underwent diabetes-oriented tests as well as non- to minimal invasive evaluation of the anatomy and function of the eye, micro- and microcirculation, endocrine system, genitourinary tract and fertility, kidney and liver profiles, detailed biochemistry lab tests and safety screening. Over 700 variables were analysed.
RESULTS: Tregs+antiCD20 group was superior to SoC control group in terms of C-peptide secretion in mixed-meal tolerance test, the time of insulin independence and remission. No clinically relevant between-groups differences were found in other performed examinations. Importantly, no severe adverse effects including tumors or deaths were reported.
CONCLUSIONS: We confirmed the long-term safety and efficacy of the therapy. Due to the superior efficacy profile, the combined treatment with Tregs and antiCD20 antibody should be considered as a routine therapy for recent-onset type 1 diabetes patients.